Voriconazole as Prophylactic Therapy in Lung Transplant Recipients

• Status: Terminated
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the safety and efficacy of Voriconazole with Itraconazole following lung transplantation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Collaborator: Pfizer
• Treatments: Voriconazole

Criteria

Inclusion Criteria:

• Bilateral-lung or single-lung transplant recipients between the ages of 18- 65 years old.

• Patients must be able to give informed consent prior to and again after transplantation

Exclusion Criteria:

• Lung transplant patients unable to give informed consent.

• Prior adverse reaction to the drug itraconazole or voriconazole